Journal article
Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
Clinical and experimental immunology, Vol.140(1), pp.1-10
04/2005
DOI: 10.1111/j.1365-2249.2004.02728.x
PMCID: PMC1809343
PMID: 15762869
Abstract
Recent studies have shed new light on a possible link between the innate activation of plasmocytoid dendritic cells and marginal zone B cells and the pathogenesis of systemic lupus erythematosus. Animal studies have identified that this response requires the Toll-like receptor 9 (TLR9). Engagement of the TLR9 by various ligands, including non-canonical CpG-motifs, can cause or aggravate pathogenic autoantibody production and cytokine secretion in lupus. Attempts to neutralize this activity either by blocking the acidification of the endosomal compartment with chloroquine and related compounds, or by preventing the interaction between the CpG-DNA sequences and TLR9 using inhibitory oligonucleotides could be a promising therapeutic option for lupus.
Details
- Title: Subtitle
- Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?
- Creators
- P Lenert - Division of Rheumatology, Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242, USA. petar-lenert@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Clinical and experimental immunology, Vol.140(1), pp.1-10
- DOI
- 10.1111/j.1365-2249.2004.02728.x
- PMID
- 15762869
- PMCID
- PMC1809343
- NLM abbreviation
- Clin Exp Immunol
- ISSN
- 0009-9104
- eISSN
- 1365-2249
- Grant note
- R01 AI047374 / NIAID NIH HHS AI047374-01A2 / NIAID NIH HHS
- Language
- English
- Date published
- 04/2005
- Academic Unit
- Immunology; Internal Medicine
- Record Identifier
- 9984094345402771
Metrics
11 Record Views